- First Line Drugs
- Second Line Drugs
Tuberculosis Treatment Market size was valued at USD 1.7 billion in 2021 and is expected to grow at a CAGR of 6.1% during 2022 to 2028. Tuberculosis is the infectious disease usually caused by the bacteria Mycobacterium tuberculosis. TB usually affects lungs and transmits to the direct contact with the sputum of the infected person. Global Tuberculosis Treatment Market is projected to grow at significant rates owing to increase in prevalence of the immunosuppressant diseases such as HIV around the globe. HIV infected patients are very susceptible to be infected by TB. According to UNAIDS statistics, about 36.7 million people were living with the HIV in 2016. Companies operating in the global market focusing on new product developments and launches to maximize their share in the market. Furthermore, collaborations and acquisitions are also key strategies adopted by the companies to strengthen their position in the global market. For instance, in August 2017, Johnson & Johnson Servieces Inc. has entered into the partnership with Institute of Microbial Technology to accelerate the discovery of novel treatments for tuberculosis. The rising number of medicine recalls is a key stumbling block to the market's expansion. Manufacturers of tuberculosis drugs face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis' drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug. Another element limiting the market's growth is the high cost of medications. Second-line therapy medications are more expensive than first-line treatment drugs, and they have more side effects and high levels of toxicity. Although advanced technologies and the development of novel therapies are expected to reduce the time it takes to treat tuberculosis, most cases can take up to 6 months to treat with currently available drugs. Despite existing medicines and ongoing TB treatment drug advances, there is a constant need to increase patients' access to appropriate TB medicines, particularly in the areas of MDR TB and paediatric TB.
Fastest Growing Market
Increase in the prevalence of the disease especially in developing countries is the major driving factor for the growth of tuberculosis treatment market globally. According to World health organization, there were 10.4 million tuberculosis cases were reported in 2016. In addition, growth in prevalence of multidrug-resistant tuberculosis and rise in awareness related to TB due to the initiatives by the various organization expected to boost the market growth over the forecast period. However, lack of reimbursement coverage in low and middle-income countries and high cost of development of drugs are expected to hamper the market growth over the forecast period.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.